September 19, 2025 a 01:01 pm
MRNA: Analysts Ratings - Moderna, Inc.
Moderna, Inc. continues to be a leading player in the biotechnology space, focusing on mRNA therapeutics and vaccines. Despite a rich pipeline, the stock's performance is under close scrutiny by analysts. Recent sentiment indicates a heavy inclination towards "Hold" ratings, reflecting cautious optimism amidst a challenging market environment.
Historical Stock Grades
As of September 2025, the analyst ratings for Moderna are predominantly "Hold". This is indicative of a neutral stance from analysts, signaling a wait-and-see approach given the current market conditions and Moderna's strategic moves within the biotech sector.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 4 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 3 |
Sentiment Development
Throughout the past months, analyst sentiment has shifted slightly towards more conservative assessments, with less emphasis on "Strong Buy" recommendations. Notably, the tilt towards "Hold" indicates a balanced view amidst evolving market dynamics and a critical eye on Moderna's development milestones.
- July 2024 to September 2025 saw an increase in "Hold" ratings from 11 to 15.
- "Strong Buy" ratings remained low, with a notable decrease from 4 in August 2024 to 1 in recent months.
- The emphasis on "Hold" suggests analysts are assessing Moderna's long-term growth potential with caution.
Percentage Trends
The percentage distribution reveals a significant trend towards conservative views, with the majority leaning toward "Hold". This is consistent with market conditions and the anticipation of further strategic developments from Moderna.
- Strong Buy has decreased from 14% in August 2024 to 5% in September 2025.
- Hold ratings have increased from 41% to 75% in the same period.
- This indicates a growing sentiment of caution amongst analysts, possibly due to market volatility or anticipated challenges in the biotech sector.
- The shift towards "Hold" highlights a desire for tangible progress in Moderna's product pipeline before revisiting stronger recommendations.
Latest Analyst Recommendations
Recent analyst activities reflect a consensus to maintain current ratings, emphasizing stability amidst market fluctuations. The lack of significant changes underscores cautious engagement with Moderna's stock.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-22 | Underperform | Underperform | Leerink Partners |
| 2025-08-04 | Equal Weight | Equal Weight | Barclays |
| 2025-07-22 | Underperform | Underperform | B of A Securities |
| 2025-05-22 | Underweight | Underweight | JP Morgan |
| 2025-05-02 | Equal Weight | Equal Weight | Barclays |
Analyst Recommendations with Change of Opinion
Highlighting key shifts in market perception, a select number of analysts have revised their outlooks for Moderna. These changes, including downgrades and upgrades, point to a reevaluation based on evolving market and company-specific factors.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-02-18 | Equal Weight | Overweight | Barclays |
| 2024-12-18 | Hold | Buy | Argus Research |
| 2024-11-18 | Buy | Hold | HSBC |
| 2024-08-06 | Hold | Sell | Deutsche Bank |
| 2024-08-05 | Sector Perform | Outperform | RBC Capital |
Interpretation
The prevailing sentiment towards "Hold" recommendations suggests growing caution amongst analysts. This sentiment indicates a market environment that requires careful consideration of both external conditions and internal development progress at Moderna. There's a noticeable hesitation to commit strongly in either bullish or bearish directions, pointing towards market uncertainty.
Conclusion
Moderna's current standing in the market is shaped by a cautious analyst outlook, with a dominant "Hold" sentiment. This reflects uncertainty and the anticipation of future developments within the company and the broader biotech industry. While there are potential growth opportunities in its mRNA technology, market participants are keenly awaiting more substantial proof of concept and product pipeline advancements to reassess their positions. Risks remain due to potential regulatory challenges and competitive pressures.